Originally Posted by: Online Community MemberThat's bad Adrian
I have also been told low risk T2, with 11 from 20 cores positive, tumours in both sides, and a family history. Doesn't inspire confidence. I will be watching my PSA result from my test in December very closely!
Hi,
Thank you and JedSee for your comments.
The last thing I want to do is make anyone who's selected AS to doubt their decision.
Although my father had prostate cancer he lived until he was 88 years and my younger brother was 60 years when he was diagnosed with T2a, Gleason (3+4) for which he had radiology.
I think a lot of the errors made in my diagnosis and delays, were down to COVID disruptions, but in my opinion there is no excuse for some of the malpractice.
On the initial information I was given, low volume low grade Gleason 6 (3+3), some "consultants call it benign" T2a staging. I believe my decision to opt for AS was a no brainer. The MDT had advised that treatment and I thought I couldn't go wrong following professional advice.
I was assured that if the disease progressed it would be so slow and that PSA checks would show any developments. I did some research on reputable sites, that showed far to many men were opting for radical treatments when AS was an adequate treatment and I didn't have a problem with living with cancer. I was happy with my decision.
During AS, communications and correspondence were poor. Telephonic consultations (COVID prevented face to face meetings) were summarised in letters to my GP but I rarely received copies of them.
As I said during the next 20 months my PSA levels remained relatively stable.
It was only when purely by chance that whilst telephoning for my latest PSA results, I was put through to the consultant who had initially diagnosed me and who had recommended the follow up MRI scan in June 2021. He then realised that this was now over a year over due.
2 months later I had that MRI scan which showed both tumours had grown T3a.
I was the given another biopsy. TP under general anaesthetic which revealed extensive disease.
These results shook me! I got copies of all my medical records and discovered that, in my opinion, errors had been made.
I was booked RARP for November 2022. I was just leaving home to go for the op when the hospital telephoned me cancelling the op, due to lack of beds. I was rescheduled for the op in Dec 2022. I was all gowned up and ready to go when the anaesthetist had concerns and the op was cancelled. These delays were almost unbearable. After the second postponement, my wife and I were shattered.
I eventually got the op in Feb this year.
I lodged an official complaint, which was a long winded process. I eventually got a reply. It was farcical. I complained two more times, as their responses contained serious inaccuracies and contradictions. They couldn't even work out that my follow up MRI had been 14 months over due, they said it was only a 2 month delay. They said that a 2 month delay would have caused very little difference to discovering disease progression. When they finally admitted their miscalculation, they didn't comment on how much a 14 month delay may have made.
That's when I complained to the Parliamentary Service and Health Ombudsman. Only to be told that due to a back log caused by COVID, there would be a five month delay before they could investigate my grievances. So I should hear something in Spring next year.
Anyway, I apologise for digressing and momentarily hijacking this conversation.
Unsurprising, I've lost a bit of faith in the NHS. Having said that. Recently I have taken time to write to two CEOs of Trusts complimenting and thanking their staff for excellent treatment I'd received for other health issues.
Whist researching AS, I found this https://gmcancer.org.uk/wp-content/uploads/2021/10/paper-3_gm-active-surveillance-protcol-v7.pdf which is quite interesting. It seems some Trusts have their own additional guidelines in managing and monitoring prostate cancer whilst others just use NICE and BAUS guidelines.
Adrian.
Edited by member 23 Nov 2023 at 14:31
| Reason: Additional text.